Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Vaccines

Vaccines

Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the type of...

Cancer Prevention

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...

Vaccinations

Vaccinations

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Ovarian cancer diagnosis within 28 days after an emergency admission to hospital: national population-based study of patient risk factors and cancer characteristics using routinely collected data in England.

BMJ oncology·2026

Same author

An advanced in vitro bladder cancer model integrating bladder cancer spheroids into a healthy human urothelium for preclinical therapeutic testing.

British journal of cancer·2026

Same author

Refining prognosis in advanced renal cell carcinoma: international real-world validation of the Meet-URO score in first-line immunotherapy combinations.

The oncologist·2026

Same author

The LDR BURST trial: a randomised controlled trial comparing the side effects of low-dose-rate brachytherapy against ultra-hypofractionated radiotherapy using spacer gel treatment in men with Cambridge Prognostic Groups 1-3 prostate cancer.

BMJ open·2026

Same author

The utility of electronic frailty index in cancer patients undergoing chemotherapy.

British journal of cancer·2026

Same author

Determinants and outcomes of ovarian cancer diagnosis following an emergency presentation: a systematic review.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026

Search research articles

Related Experiment Video

Updated: May 13, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Prostate cancer vaccines.

Agnieszka Michael¹, Kate Relph, Nicola Annels

¹Oncology Group, Faculty of Health & Medical Sciences, Leggett Building, University of Surrey, Guildford, GU2 7WG, UK. a.michael@surrey.ac.uk

Expert Review of Vaccines

|March 19, 2013

Summary

The first therapeutic cancer vaccine, sipuleucel-T, was approved in 2010 for prostate cancer. This review examines the evolution of prostate cancer vaccines as a model for other cancers and discusses challenges.

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration

Published on: April 27, 2018

Related Experiment Videos

Last Updated: May 13, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration

Published on: April 27, 2018

Area of Science:

Oncology
Immunology
Vaccinology

Background:

Prostate cancer serves as an excellent model for therapeutic cancer vaccine development.
The slow progression of prostate cancer allows for sustained vaccine therapy and robust antitumor responses.
Established humoral and cellular immunity to cancer antigens in prostate cancer supports vaccine strategies.

Purpose of the Study:

To review the evolution of therapeutic cancer vaccines for prostate cancer.
To highlight prostate cancer vaccines as a prototype for other cancer types.
To discuss the challenges and future directions in cancer vaccine development.

Main Methods:

Review of historical data and clinical trial outcomes for prostate cancer vaccines.
Analysis of immunological responses to cancer vaccines in prostate cancer patients.
Examination of the role of biomarkers in assessing vaccine efficacy.

Main Results:

Sipuleucel-T, the first therapeutic cancer vaccine, was approved in 2010 for castration-refractory prostate cancer.
Prostate cancer exhibits characteristics favorable for vaccine therapy, including demonstrable immune responses and slow progression.
Serum cancer biomarkers aid in evaluating treatment response and stratifying patient risk.

Conclusions:

Prostate cancer vaccine development offers valuable insights and a prototype for broader cancer vaccine research.
Continued research is essential to overcome challenges and advance the field of therapeutic cancer vaccines.
The integration of immunological understanding and clinical application is key to successful cancer vaccine strategies.